Brian K Whiteley

USPTO Granted Patents = 14 (Patent Applications = 1)

EPO Patents = 9 (Patent Applications = 9)

Average Co-Inventor Count = 8.0

ph-index = 3

Forward Citations = 45(Granted Patents)

Company Filing History:

11 out of 3,681

Bristol-myers Squibb Compnay

patents

2 out of 1,827

Sanofi-a Ventis Deutschland Gmbh

patents

1 out of 207

Aventis Pharmaceuticals Inc.

patents

Years Active: 2007-2024

Loading Chart...

14 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12030878 - Substituted indole ether compounds (2024-07-09),

2. 11998537 - Substituted indole dimer compounds (2024-06-04),

3. 11878975 - Substituted indole compounds useful as TLR inhibitors (2024-01-23),

4. 11820768 - 4-azaindole compounds (2023-11-21),

5. 11739098 - Substituted indole compounds (2023-08-29),

6. 11447466 - Substituted indole compounds useful as inhibitors of TLR7/8/9 (2022-09-20),

7. 11420958 - Aryl and heteroaryl substituted indole compounds (2022-08-23),

8. 11299501 - Diazaindole compounds (2022-04-12),

9. 11053244 - 4-azaindole compounds (2021-07-06),

10. 10730877 - 4-Azaindole compounds (2020-08-04),

11. 10660877 - Pyridyl substituted indole compounds (2020-05-26),

12. 7994168 - Hexahydro-pyrazino[1,2-A]pyrimidine-4,7-dione derivatives substituted with amino acids (2011-08-09),

13. 7652007 - Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments (2010-01-26),

14. 7169925 - Indole derivatives as interleukin-4 gene expression inhibitors (2007-01-30),

Title: The Innovative Contributions of Brian K. Whiteley

Introduction

Brian K. Whiteley is a notable inventor based in Lebanon, NJ (US), recognized for his significant contributions to the field of pharmaceutical compounds. With a total of 14 patents to his name, Whiteley has made strides in developing compounds that target inflammatory and autoimmune diseases.

Latest Patents

Among his latest patents are the "Substituted indole ether compounds," which disclose compounds of Formula (I) N-oxides, or salts thereof. These compounds are designed to inhibit signaling through Toll-like receptors 7, 8, or 9, and are particularly useful in treating various inflammatory and autoimmune diseases. Another significant patent is for "Substituted indole dimer compounds," which also includes compounds of Formula (I) N-oxides, or salts thereof. Similar to his previous work, these compounds serve as inhibitors of signaling through Toll-like receptors and have applications in the treatment of inflammatory and autoimmune conditions.

Career Highlights

Throughout his career, Brian K. Whiteley has worked with prominent companies in the pharmaceutical industry, including Bristol-Myers Squibb Company and Sanofi-Aventis Deutschland GmbH. His experience in these organizations has contributed to his expertise in developing innovative pharmaceutical solutions.

Collaborations

Whiteley has collaborated with notable colleagues such as Alaric J. Dyckman and Dharmpal S. Dodd, further enhancing his work in the field of pharmaceutical inventions.

Conclusion

Brian K. Whiteley's innovative work in developing pharmaceutical compounds has made a significant impact on the treatment of inflammatory and autoimmune diseases. His contributions continue to advance the field and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.